Aggregation‐induced emission polymer systems with circularly polarized luminescence

Abstract Functional materials with circularly polarized luminescence (CPL) have attracted tremendous attention due to their promising applications in three‐dimensional displays, chiral recognition and catalysis, photoelectronic devices, contrast imaging, information encryption, and other fields. Among various CPL‐active materials, polymeric systems with aggregation‐induced emission (AIE) have emerged as excellent candidates because of their efficient aggregate‐state fluorescence, large solid‐state dissymmetry factor, excellent processibility, diversified self‐assembly behaviors, and readily switchable CPL properties. This review summarizes and discusses the recent progress as well as future perspective of diverse AIE polymer systems with CPL, including CPL‐active covalent AIE polymers, CPL‐active supramolecular AIE polymers, and AIEgen/polymer composites with CPL. According to the location or introduction method of AIEgen in polymer structures, this review further divides CPL‐active covalent AIE polymers into three categories, including polymers with AIEgen in main chains, polymers with AIEgen in side chains, and CPL‐active polymers with clusterization‐triggered emission. CPL‐active supramolecular AIE polymers are discussed based on the driving force for the formation of supramolecular polymers, including host–guest interactions, metal coordination, and other non‐covalent interactions. Moreover, examples on the construction of CPL‐active AIEgen/polymer composites by physically mixing AIEgens with chiral (supra)polymers are also presented. This review is anticipated to provide readers with an overall view on the design strategies of CPL‐active AIE polymers, and facilitate further research on the development of CPL materials and AIE polymers with advanced applications

Effects of C/N Ratio on Lignocellulose Degradation and Enzyme Activities in Aerobic Composting

Lignocellulosic materials have a complex physicochemical composition and structure that reduces their decomposition rate and hinders the formation of humic substances during composting. Therefore, a composting experiment was conducted to evaluate the effects of different C/N ratios on lignocellulose (cellulose, hemicellulose and lignin) degradation and the activities of corresponding enzymes during aerobic composting. The study had five C/N ratios, namely, T1 (C/N ratio of 15), T2 (C/N ratio of 20), T3 (C/N ratio of 25), T4 (C/N ratio of 30) and T5 (C/N ratio of 35). The results showed that treatments T3 and T4 had the highest rate of degradation of cellulose and hemicellulose, while treatment T3 had the highest rate of degradation of lignin. Among the five treatments, treatment T3 enhanced the degradation of the lignocellulose constituents, indicating a degradation rate of 6.86–35.17%, 15.63–44.08% and 31.69–165.60% for cellulose, hemicellulose and lignin, respectively. The degradation of cellulose and lignin occurred mainly at the thermophilic and late mesophilic phases of composting, while hemicellulose degradation occurred at the maturation phase. Treatment T3 was the best C/N ratio to stimulate the activities of manganese peroxidase, lignin peroxidase, polyphenol oxidase and peroxidase, which in turn promoted lignocellulose degradation

Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis

Abstract Background Some Chinese patients with esophageal squamous cell carcinomaare often treated with single-agent concurrent chemoradiotherapy. However, no results have been reported from randomized controlled clinical trials comparing single-agent with double-agent concurrent chemoradiotherapy. It therefore remains unclear whether these regimens are equally clinically effective. In this study, we retrospectively analyzed and compared the therapeutic effects of single-agent and double-agent concurrent chemoradiotherapy in patients with unresectable esophageal squamous cell carcinoma. Methods This study enrolled 168 patients who received definitive concurrent chemoradiotherapy for locally advanced unresectable esophageal squamous carcinoma at 10 hospitals between 2010 and 2015. We evaluated survival time and toxicity. The Kaplan-Meier method was used to estimate survival data. The log-rank test was used in univariate analysis A Cox proportional hazards regression model was used to conduct a multivariate analysis of the effects of prognostic factors on survival. Results In this study, 100 (59.5%) and 68 patients (40.5%) received single-agent and dual-agent combination chemoradiotherapy, respectively. The estimate 5-year progression-free survival (PFS) rate and overall survival (OS) rate of dual-agent therapy was higher than that of single-agent therapy (52.5% and 40.9%, 78.2% and 60.7%, respectively), but there were no significant differences (P = 0.367 and 0.161, respectively). Multivariate analysis showed that sex, age,and radiotherapy dose had no significant effects on OS or PFS. Only disease stage was associated with OS and PFS in the multivariable analysis (P = 0.006 and 0.003, respectively). In dual-agent group, the incidence of acute toxicity and the incidence of 3 and4 grade toxicity were higher than single-agent group. Conclusion The 5-year PFS and OS rates of dual-agent therapy were higher than those of single-agent concurrent chemoradiotherapy for patients with unresectable esophageal squamous cell carcinoma; however, there were no significant differences in univariate analysis and multivariable analysis. Single-agent concurrent chemotherapy had less toxicity than a double-drug regimen. Therefore, we suggest that single therapis not inferior to dual therapy y. In the future, we aim to confirm our hypothesis through a prospective randomized study

Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer

Ovarian cancer (OC) is one of the most lethal malignancies of the female reproductive system. OC patients are usually diagnosed at advanced stages due to the lack of early diagnosis. The standard treatment for OC includes a combination of debulking surgery and platinum-taxane chemotherapy, while several targeted therapies have recently been approved for maintenance treatment. The vast majority of OC patients relapse with chemoresistant tumors after an initial response. Thus, there is an unmet clinical need to develop new therapeutic agents to overcome the chemoresistance of OC. The anti-parasite agent niclosamide (NA) has been repurposed as an anti-cancer agent and exerts potent anti-cancer activities in human cancers including OC. Here, we investigated whether NA could be repurposed as a therapeutic agent to overcome cisplatin-resistant (CR) in human OC cells. To this end, we first established two CR lines SKOV3CR and OVCAR8CR that exhibit the essential biological characteristics of cisplatin resistance in human cancer. We showed that NA inhibited cell proliferation, suppressed cell migration, and induced cell apoptosis in both CR lines at a low micromole range. Mechanistically, NA inhibited multiple cancer-related pathways including AP1, ELK/SRF, HIF1, and TCF/LEF, in SKOV3CR and OVCAR8CR cells. NA was further shown to effectively inhibit xenograft tumor growth of SKOV3CR cells. Collectively, our findings strongly suggest that NA may be repurposed as an efficacious agent to combat cisplatin resistance in chemoresistant human OC, and further clinical trials are highly warranted

Viral RNA <i>N</i>⁶-methyladenosine modification modulates both innate and adaptive immune responses of human respiratory syncytial virus

Human respiratory syncytial virus (RSV) is the leading cause of respiratory tract infections in humans. A well-known challenge in the development of a live attenuated RSV vaccine is that interferon (IFN)-mediated antiviral responses are strongly suppressed by RSV nonstructural proteins which, in turn, dampens the subsequent adaptive immune responses. Here, we discovered a novel strategy to enhance innate and adaptive immunity to RSV infection. Specifically, we found that recombinant RSVs deficient in viral RNA N6-methyladenosine (m6A) and RSV grown in m6A methyltransferase (METTL3)-knockdown cells induce higher expression of RIG-I, bind more efficiently to RIG-I, and enhance RIG-I ubiquitination and IRF3 phosphorylation compared to wild-type virion RNA, leading to enhanced type I IFN production. Importantly, these m6A-deficient RSV mutants also induce a stronger IFN response in vivo, are significantly attenuated, induce higher neutralizing antibody and T cell immune responses in mice and provide complete protection against RSV challenge in cotton rats. Collectively, our results demonstrate that inhibition of RSV RNA m6A methylation enhances innate immune responses which in turn promote adaptive immunity.</p